Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Bill Kelly

FDA accepts Melinta application re BAXDELA®

Melinta Therapeutics reports that the FDA has accepted a supplemental New Drug Application for BAXDELA® (delafloxacin) for priority review. The application seeks to expand the current indication for...

| By Bill Kelly

Alexion reports progress with ULTOMIRIS®

Alexion reports that the FDA  has accepted for priority review the company’s supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, for...

| By Bill Kelly

CT Pavilion shines at 2019 BIO Convention

The BIO International Convention, one of the world’s largest forums for the biotech sector, welcomed a record number of attendees to Philadelphia earlier this month. Connecticut was center...

| By Bill Kelly

SpringWorks and BeiGene form new entity, MapKure

MapKure intends to develop BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating B-RAF mutations including V600 BRAF mutations,...

| By Kelley Gipson

Artizan returns to roots in New Haven

Artizan Biosciences, a biotechnology company focused on curing inflammatory bowel disease by targeting bacteria that inhabit the gastrointestinal system, is returning to its New Haven...

| By Kelley Gipson

Pfizer marks 60 years of R&D in Groton

Pfizer’s Groton site has had a hand in the discovery and development of such medicines as Zoloft and Zithromax and, more recently, Xalkori and Xeljanz....

| By Bill Kelly

Achillion schedules presentations on progress

Achillion Pharmaceuticals reports that Brian Di Donato, Chief Financial Officer, and Steven Zelenkofske, D.O., Chief Medical Officer, will present at the JMP Securities Life Sciences...

| By Bill Kelly

Artizan announces corporate progress and financing

Artizan Biosciences has announced corporate and financial updates: Artizan has completed its Series A funding, bringing the total raised to date to $12 million. Paul...

| By Bill Kelly

UConn looks at bioinformatics and bone health

A team of University of Connecticut researchers has received a $2.8 million grant from the National Institutes of Health for a five-year project studying how...